News und Analysen
Why Snap, Regal Entertainment Group, and Revance Therapeutics Jumped Today
Tuesday was a down day for most of the stock market, with major benchmarks finishing with modest losses of half a percent or less. The NYSE Composite pulled back from the record highs it reached....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
Shares of specialty pharmaceutical developer Collegium Pharmaceutical (NASDAQ: COLL) rose over 23% today after the company announced that it will acquire the pain drug Nucynta from Depomed....
Why Revance Therapeutics Is Soaring Today
In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10....
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
Why Ra Pharmaceuticals, Inc. Got Hammered Today
Ra Pharmaceuticals (NASDAQ: RARX) characterized its interim phase 2 data testing RA101495 SC in patients with paroxysmal nocturnal hemoglobinuria (PNH) as "positive," but the market sees it....
Why Endocyte, Inc. Stock Briefly Spiked Today
Shares of the clinical-stage biotech Endocyte (NASDAQ: ECYT) briefly rose by as much as 16% Monday on more than double the average daily volume. The catalyst? Investors appear to have noticed a....
1 High-Risk Penny Stock That May Be Worth Buying
Penny stocks, or stocks with a sub-$5 share price, generally aren't my cup of tea. These types of companies tend to be far too risky to make them worthy of serious investment consideration. The....
BASTIDE : Déclaration du nombre d'actions et de droits de vote au 30.11.2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
3 Stocks That Quadrupled
The stock market continues to put on a clinic about how to stomp all over expectations. The Dow Jones Industrial Average is up 25% this year and the S&P 500 is 20% higher, but stack them up....
Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling....
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG)....
Why Intuitive Surgical, Inc. Shareholders Have Something to Worry About
Surgeons around the globe will perform around 867,000 procedures using Intuitive Surgical, Inc.'s (NASDAQ: ISRG) robots this year, making this company the undisputed champion of robotic surgery,....
Why Intuitive Surgical, Inc. Shareholders Have Something to Worry About
Surgeons around the globe will perform around 867,000 procedures using Intuitive Surgical, Inc.'s (NASDAQ: ISRG) robots this year, making this company the undisputed champion of robotic surgery,....
Why Intuitive Surgical, Inc. Shareholders Have Something to Worry About
Surgeons around the globe will perform around 867,000 procedures using Intuitive Surgical, Inc.'s (NASDAQ: ISRG) robots this year, making this company the undisputed champion of robotic surgery,....
3 Highest Growth Stocks in the Market Today
I'm constantly scanning the market for stocks that promise hyper growth in the years ahead. One tool that I use to find these high growth companies is Finviz. With that in mind, I recently ran a....
Market-Moving News Is on Tap for Seattle Genetics
Seattle Genetics (NASDAQ: SGEN) Adcetris is already a successful drug with global sales of about $600 million, but sales could climb even higher if the Food and Drug Administration approves its....
Market-Moving News Is on Tap for Seattle Genetics
Seattle Genetics (NASDAQ: SGEN) Adcetris is already a successful drug with global sales of about $600 million, but sales could climb even higher if the Food and Drug Administration approves its....
3 Top Stocks Under $5
Although market cap is a more important metric to consider when determining the future value of a company's share price, it's not uncommon for investors to think that a lower stock price....